Obesity – Page 7

Biden Administration Proposes Expanded Coverage of Anti-Obesity Medications for Medicare and Medicaid Enrollees

5 months ago talkbio0Tagged Biden administration, Drug Prescriptions, Health Care Reform, Medicaid, Medicare, Obesity

Biden Administration, Obesity Drug Coverage, Medicare, Medicaid, Prescription Drug Costs, Healthcare Reform

Biohaven’s Taldefgrobep Alfa Shifts Focus to Obesity After Missing Primary Endpoint in Spinal Muscular Atrophy Phase 3 Trial

5 months ago talkbio0Tagged Alfa, Body Composition, Bone and Bones, density, GDF8 protein, human, Inhibitor, lean, Obesity, Phase 3 trial, Spinal Muscular Atrophy

Biohaven, taldefgrobep alfa, spinal muscular atrophy (SMA), obesity, myostatin inhibitor, phase 3 trial, body composition, lean muscle mass, bone density.

Biohaven’s Taldefgrobep Alfa Misses Primary Endpoint in Phase 3 SMA Trial, Eyes FDA Discussions and Obesity Indication

5 months ago talkbio0Tagged Discussion (procedure), Indication of (contextual qualifier), Obesity, Phase 3 trial, Spinal Muscular Atrophy, Talditercept alfa, United States Food and Drug Administration

Biohaven, Taldefgrobep Alfa, Spinal Muscular Atrophy (SMA), Phase 3 Trial, FDA Discussions, Obesity Indication

Enveda Secures $130 Million in Funding for Innovative Therapies in Inflammation, Obesity, and Beyond

5 months ago talkbio0Tagged Drug Development, Enveda, I&I, Inflammation, Microsoft-backed, Obesity, Pharma

Enveda, Microsoft-backed, $130M funding, Inflammation & Immunology (I&I), obesity, biotech, pharma, drug development

Versant Ventures Launches Pep2Tango Therapeutics with Revolutionary Tetra-Receptor Agonist Approach for Obesity Treatment

5 months ago talkbio0Tagged Amylin, Calcitonin Receptor, GIP/, GLP-1, muscle mass, Next, Next-generation weight loss therapies, Obesity, Pep2Tango, Peptides, Tetra-receptor, Ventures, Versant

Obesity treatment, Tetra-receptor agonist peptides, GLP-1/ GIP/ amylin/ and calcitonin receptors, Muscle mass preservation, Next-generation weight loss therapies, Versant Ventures, Pep2Tango Therapeutics Inc.

Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics

5 months ago talkbio0Tagged Ampersand, Biomedicines, Drug Development, Flagship, Montai, Non-Small Cell Lung Carcinoma, Obesity, Pfizer, Pioneering, strategic partnership

Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer

GUBamy, a Weekly Amylin Agonist, Shows Promising Weight Loss and Tolerability in Phase 1 Trial

6 months ago talkbio0Tagged Agonist, Amylin, GUBamy, long-acting, Obesity, phase 1 trial, Weight Loss

Amylin agonist, Obesity treatment, Weight loss, Phase 1 trial, GUBamy, Long-acting amylin agonist

Metsera Secures $215M to Accelerate Obesity Drug Development

6 months ago talkbio0Tagged biotech, Glucagon-Like Peptide 1, Metabolic Diseases, Metsera, Obesity

Metsera, Obesity Drug, Funding, Biotech, GLP-1, Metabolic Disease

Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data

6 months ago talkbio0Tagged Glucagon-Like Peptide 1, Metsera, NuSH, Obesity, Peptides, Series B

Metsera, Series B funding, weight loss, obesity treatment, GLP-1 drugs, NuSH peptides

Pharmaceutical Giants Eli Lilly and Novo Nordisk Face Challenges Despite Strong Sales Growth

6 months ago talkbio0Tagged competition, Drug Industry, Eli, Eli Lilly, financial results, issues, Market, Nordisk, Obesity, Pricing, Q3 2024, Weight loss therapies

Eli Lilly, Novo Nordisk, Q3 2024 financial results, Obesity drugs, Weight loss therapies, Pharmaceutical industry challenges, Market competition, Supply pressures, Pricing issues